Bayer may be next in line for anticoagulant lawsuits

| | Cardiovascular Business | Patient Care

Now it is Bayer’s turn. Less than a month after Boehringer Ingelheim set aside $650 million to settle lawsuits in the U.S. over its anticoagulant dabigatran (Pradaxa), rival Bayer received its first round of similar claims over rivaroxaban (Xarelto), according to the Frankfurter Allgemeine Zeitung newspaper.

Bayer faces law suits in United States over Xarelto -paper

Related Content

FDA and Boston Scientific issue urgent alert about pacemaker failures following 2 deaths
Concomitant ablation surgery during heart operations boosts long-term survival
Cardiologist explores why colchicine failed to help heart attack patients
Bioresorbable BTK stent superior to ballon angioplasty at 2 years
Most heart failure patients miss out on guideline-recommended palliative care
Cardiologist behind EARLY TAVR explains how proactive treatment improves patient outcomes

Around the web

Radiology Business
Key takeaways from RSNA 2024 for AI, CT, MRI and the radiology staffing shortage

Several key trends were evident at the Radiological Society of North America 2024 meeting, including new CT and MR technology and evolving adoption of artificial intelligence.

Health Imaging
Use of AI opportunistic screening in CT for cardiovascular disease

Ron Blankstein, MD, professor of radiology, Harvard Medical School, explains the use of artificial intelligence to detect heart disease in non-cardiac CT exams.

Health Imaging
New imaging protocols proposed to curb rise of cardiovascular infections

Eleven medical societies have signed on to a consensus statement aimed at standardizing imaging for suspected cardiovascular infections.